Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients.

Pouderoux C, Becker A, Goutelle S, Lustig S, Triffault-Fillit C, Daoud F, Fessy MH, Cohen S, Laurent F, Chidiac C, Valour F, Ferry T; Lyon Bone and Joint Infection Study Group .

J Antimicrob Chemother. 2019 Jul 1;74(7):2060-2064. doi: 10.1093/jac/dkz104.

PMID:
31220276
2.

Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.

Benech N, Dumitrescu O, Conrad A, Balsat M, Paubelle E, Ducastelle-Lepretre S, Labussière-Wallet H, Salles G, Cohen S, Goutelle S, Ader F; Lyon HEMINF Study Group .

J Antimicrob Chemother. 2019 Jun 20. pii: dkz248. doi: 10.1093/jac/dkz248. [Epub ahead of print]

PMID:
31219562
3.

Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).

Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, Goutelle S, Lefeuvre S, Mongardon N, Roger C, Scala-Bertola J, Lemaitre F, Garnier M.

Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9. Review.

4.

Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection.

Bricca R, Goutelle S, Roux S, Gagnieu MC, Becker A, Conrad A, Valour F, Laurent F, Triffault-Fillit C, Chidiac C, Ferry T; Lyon Bone and Joint Infection Study Group .

J Antimicrob Chemother. 2019 Apr 1;74(4):1012-1020. doi: 10.1093/jac/dky541.

PMID:
30629193
5.

A practical approach to tuberculosis diagnosis and treatment in liver transplant recipients in a low-prevalence area.

Bosch A, Valour F, Dumitrescu O, Dumortier J, Radenne S, Pages-Ecochard M, Chidiac C, Ferry T, Perpoint T, Miailhes P, Conrad A, Goutelle S, Ader F; Lyon TB study Group.

Med Mal Infect. 2019 Jun;49(4):231-240. doi: 10.1016/j.medmal.2018.11.013. Epub 2018 Dec 24. Review.

PMID:
30591271
6.

A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Tod M, Goutelle S, Bleyzac N, Bourguignon L.

Clin Pharmacokinet. 2019 Apr;58(4):503-523. doi: 10.1007/s40262-018-0711-0.

PMID:
30194612
7.

Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.

Philippe M, Neely M, Rushing T, Bertrand Y, Bleyzac N, Goutelle S.

Bone Marrow Transplant. 2019 Mar;54(3):448-457. doi: 10.1038/s41409-018-0281-7. Epub 2018 Aug 14.

PMID:
30108322
8.

Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy.

Triffault-Fillit C, Valour F, Guillo R, Tod M, Goutelle S, Lustig S, Fessy MH, Chidiac C, Ferry T; Lyon BJI Study Group.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00163-18. doi: 10.1128/AAC.00163-18. Print 2018 Oct.

9.

Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.

Genestet C, Bernard-Barret F, Hodille E, Ginevra C, Ader F, Goutelle S, Lina G, Dumitrescu O; Lyon TB study group.

Tuberculosis (Edinb). 2018 Jul;111:67-70. doi: 10.1016/j.tube.2018.05.014. Epub 2018 May 22.

PMID:
30029917
10.

Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.

Fournier A, Goutelle S, Que YA, Eggimann P, Pantet O, Sadeghipour F, Voirol P, Csajka C.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00505-18. doi: 10.1128/AAC.00505-18. Print 2018 Sep.

11.

Determinants of amikacin first peak concentration in critically ill patients.

Boidin C, Jenck S, Bourguignon L, Torkmani S, Roussey-Jean A, Ledochowski S, Marry L, Ammenouche N, Dupont H, Marçon F, Allaouchiche B, Bohé J, Lepape A, Goutelle S, Friggeri A.

Fundam Clin Pharmacol. 2018 Dec;32(6):669-677. doi: 10.1111/fcp.12374. Epub 2018 May 23.

PMID:
29660162
12.

Comment on: MIC-based dose adjustment: facts and fables.

Goutelle S, Genestet C, Ader F, Lina G, Dumitrescu O.

J Antimicrob Chemother. 2018 Sep 1;73(9):2584-2585. doi: 10.1093/jac/dky131. No abstract available.

PMID:
29659869
13.

Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Fermier N, Bourguignon L, Goutelle S, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Dec;57(12):1581-1591. doi: 10.1007/s40262-018-0651-8.

PMID:
29572664
14.

[Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach].

Lafarge L, Bourguignon L, Bernard N, Vial T, Dehan-Moya MJ, De La Gastine B, Goutelle S.

Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):91-97. doi: 10.1016/j.ancard.2018.02.001. Epub 2018 Mar 12. French.

PMID:
29544975
15.

Continuous intravenous vancomycin in children with normal renal function hospitalized in hematology-oncology: prospective validation of a dosing regimen optimizing steady-state concentration.

Hoegy D, Goutelle S, Garnier N, Rénard C, Faure-Conter C, Bergeron C, Bertrand Y, Bleyzac N.

Fundam Clin Pharmacol. 2018 Jun;32(3):323-329. doi: 10.1111/fcp.12344. Epub 2018 Mar 24.

PMID:
29315849
16.

Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection.

Goutelle S, Valour F, Gagnieu MC, Laurent F, Chidiac C, Ferry T; Lyon Bone and Joint Infection Study Group.

J Antimicrob Chemother. 2018 Apr 1;73(4):987-994. doi: 10.1093/jac/dkx477.

PMID:
29244077
17.

Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.

Cazaubon Y, Venisse N, Mimoz O, Maire P, Ducher M, Bourguignon L, Goutelle S.

J Antimicrob Chemother. 2017 Oct 1;72(10):2804-2812. doi: 10.1093/jac/dkx242.

PMID:
29091222
18.

Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using In Vitro Experiments and Response-Surface Modeling.

Genestet C, Ader F, Pichat C, Lina G, Dumitrescu O, Goutelle S.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01413-17. doi: 10.1128/AAC.01413-17. Print 2018 Jan.

19.

The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.

Hodille E, Rose W, Diep BA, Goutelle S, Lina G, Dumitrescu O.

Clin Microbiol Rev. 2017 Oct;30(4):887-917. doi: 10.1128/CMR.00120-16. Review.

20.

Prevalence and Risk Factors of Drug-Associated Corrected QT Prolongation in Elderly Hospitalized Patients: Results of a Retrospective Analysis of Data Obtained Over 6 Months.

Maison O, de la Gastine B, Dayot L, Goutelle S.

Drugs Aging. 2017 Jul;34(7):545-553. doi: 10.1007/s40266-017-0467-5.

PMID:
28577045
21.

Mechanisms of drug-drug interaction between rifampicin and fusidic acid.

Bel F, Bourguignon L, Tod M, Ferry T, Goutelle S.

Br J Clin Pharmacol. 2017 Aug;83(8):1862-1864. doi: 10.1111/bcp.13277. Epub 2017 Apr 12. No abstract available.

22.

Factors associated with changes in exposure to anticholinergic and sedative medications in elderly hospitalized patients: multicentre longitudinal study.

Dauphinot V, Faure R, Bourguignon L, Goutelle S, Krolak-Salmon P, Mouchoux C.

Eur J Neurol. 2017 Mar;24(3):483-490. doi: 10.1111/ene.13228. Epub 2016 Dec 27.

PMID:
28026898
23.

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?

Tod M, Goutelle S, Bourguignon L, Bleyzac N.

CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):226. doi: 10.1002/psp4.12164. Epub 2017 Apr 11. No abstract available.

24.

A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

Tod M, Bourguignon L, Bleyzac N, Goutelle S.

AAPS J. 2017 Mar;19(2):497-509. doi: 10.1208/s12248-016-0021-0. Epub 2016 Dec 6.

PMID:
27924615
25.

Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients.

Bel Kamel A, Bourguignon L, Marcos M, Ducher M, Goutelle S.

Ther Drug Monit. 2017 Feb;39(1):83-87. doi: 10.1097/FTD.0000000000000359.

PMID:
27861313
26.

Implications of using the MDRD or CKD-EPI equation instead of the Cockcroft-Gault equation for estimating renal function and drug dosage adjustment in elderly patients.

Cartet-Farnier E, Goutelle-Audibert L, Maire P, De la Gastine B, Goutelle S.

Fundam Clin Pharmacol. 2017 Feb;31(1):110-119. doi: 10.1111/fcp.12241. Epub 2016 Oct 5.

PMID:
27599753
27.

A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Philippe M, Neely M, Bertrand Y, Bleyzac N, Goutelle S.

Clin Pharmacokinet. 2017 Apr;56(4):435-447. doi: 10.1007/s40262-016-0448-6.

PMID:
27585476
28.

Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.

Bourguignon L, Cazaubon Y, Debeurme G, Loue C, Ducher M, Goutelle S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4563-7. doi: 10.1128/AAC.00303-16. Print 2016 Aug.

29.

Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study.

Lalande L, Bourguignon L, Maire P, Goutelle S.

J Theor Biol. 2016 Jun 21;399:43-52. doi: 10.1016/j.jtbi.2016.03.038. Epub 2016 Apr 5.

PMID:
27059890
30.

Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Gabriel L, Tod M, Goutelle S.

Clin Pharmacokinet. 2016 Aug;55(8):977-90. doi: 10.1007/s40262-016-0371-x.

PMID:
26936044
31.

Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections.

Goutelle S, Roux S, Gagnieu MC, Valour F, Lustig S, Ader F, Laurent F, Chidiac C, Ferry T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3148-51. doi: 10.1128/AAC.02597-15. Print 2016 May.

32.

Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, Schumitzky A, Bleyzac N, Goutelle S.

Ther Drug Monit. 2016 Jun;38(3):332-42. doi: 10.1097/FTD.0000000000000276.

33.

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.

Bleyzac N, Cuzzubbo D, Rénard C, Garnier N, Dubois V, Domenech C, Goutagny MP, Plesa A, Grardel N, Goutelle S, Janoly-Duménil A, Bertrand Y.

Bone Marrow Transplant. 2016 May;51(5):698-704. doi: 10.1038/bmt.2015.350. Epub 2016 Jan 25.

PMID:
26808568
34.

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Grard S, Catho G, Valour F, Bouaziz A, Perpoint T, Braun E, Biron F, Miailhes P, Ferry T, Chidiac C, Souquet PJ, Couraud S, Lina G, Goutelle S, Veziris N, Dumitrescu O, Ader F.

Open Forum Infect Dis. 2015 Dec 22;2(4):ofv175. doi: 10.1093/ofid/ofv175. eCollection 2015 Dec.

35.

Pharmacokinetic and Analytical Issues in Busulfan Area Under the Curve Estimation and Simulation.

Philippe M, Bleyzac N, Goutelle S.

Biol Blood Marrow Transplant. 2016 Jan;22(1):185. doi: 10.1016/j.bbmt.2015.09.022. Epub 2015 Sep 30. No abstract available.

36.

Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.

Cazaubon Y, Bourguignon L, Goutelle S, Martin O, Maire P, Ducher M.

Fundam Clin Pharmacol. 2015 Dec;29(6):615-24. doi: 10.1111/fcp.12156. Epub 2015 Oct 26.

PMID:
26406268
37.

Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Philippe M, Goutelle S, Guitton J, Fonrose X, Bergeron C, Girard P, Bertrand Y, Bleyzac N.

Bone Marrow Transplant. 2016 Jan;51(1):72-8. doi: 10.1038/bmt.2015.218. Epub 2015 Sep 21.

PMID:
26389835
38.

Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Lalande L, Bourguignon L, Bihari S, Maire P, Neely M, Jelliffe R, Goutelle S.

Antimicrob Agents Chemother. 2015 Sep;59(9):5181-9. doi: 10.1128/AAC.00462-15. Epub 2015 Jun 15.

39.

A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Steelandt J, Jean-Bart E, Goutelle S, Tod M.

Clin Pharmacokinet. 2015 Dec;54(12):1245-58. doi: 10.1007/s40262-015-0288-9.

PMID:
26070946
40.

Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.

Philippe M, Hénin E, Bertrand Y, Plantaz D, Goutelle S, Bleyzac N.

AAPS J. 2015 Sep;17(5):1157-67. doi: 10.1208/s12248-015-9779-8. Epub 2015 May 15.

41.

[Subcutaneous administration of levetiracetam in geriatrics].

Maison O, De la Gastine B, Peter-Derex L, Berger C, Goutelle S.

Rev Neurol (Paris). 2015 Apr;171(4):398-9. doi: 10.1016/j.neurol.2015.01.567. Epub 2015 Apr 4. French. No abstract available.

PMID:
25847398
42.

Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely MN, Goutelle S.

Antimicrob Agents Chemother. 2015;59(6):2986-94. doi: 10.1128/AAC.04132-14. Epub 2015 Mar 9.

43.

A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example.

Clewe O, Goutelle S, Conte JE Jr, Simonsson US.

Eur J Clin Pharmacol. 2015 Mar;71(3):313-9. doi: 10.1007/s00228-014-1798-3. Epub 2015 Jan 27.

44.

Quantitative methods for prediction of the effect of cytochrome P450 gene polymorphisms on substrate drug exposure.

Goutelle S, Tod M.

Clin Pharmacokinet. 2015 Mar;54(3):319-20. doi: 10.1007/s40262-014-0217-3. No abstract available.

PMID:
25559340
45.

[Lower limb edema during valpromide treatment: case report and literature review].

Gabriel L, Darcissac C, Goutelle S, Sève P, Vial T, de La Gastine B.

Rev Med Interne. 2015 Oct;36(10):698-700. doi: 10.1016/j.revmed.2014.11.011. Epub 2014 Dec 24. Review. French.

PMID:
25544148
46.

Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children.

Bernard E, Goutelle S, Bertrand Y, Bleyzac N.

Ann Pharmacother. 2014 Dec;48(12):1580-4. doi: 10.1177/1060028014550644. Epub 2014 Oct 3.

PMID:
25280976
47.

The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy.

Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely MN.

Curr Pharm Des. 2014;20(39):6191-206. Review.

PMID:
25190098
48.

Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort.

Dauphinot V, Faure R, Omrani S, Goutelle S, Bourguignon L, Krolak-Salmon P, Mouchoux C.

J Clin Psychopharmacol. 2014 Oct;34(5):565-70. doi: 10.1097/JCP.0000000000000195. Erratum in: J Clin Psychopharmacol. 2017 Feb;37(1):26.

PMID:
25133790
49.

Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.

Goutelle S, Sidolle E, Ducher M, Caron J, Timour Q, Nony P, Gouraud A.

Drugs Aging. 2014 Aug;31(8):601-9. doi: 10.1007/s40266-014-0188-y.

PMID:
24923384
50.

Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile.

Bleyzac N, Kebaili K, Mialou V, Bertrand Y, Goutelle S.

Ther Drug Monit. 2014 Dec;36(6):724-9. doi: 10.1097/FTD.0000000000000084.

PMID:
24739665

Supplemental Content

Loading ...
Support Center